A year after raising $64 million to expand its Foundry Row operations, Kestrel Biologics has reached the first real test of whether that bet will pay off: its lead gene-therapy candidate has cleared an early safety milestone in its Phase 1 trial.
Kestrel Biologics said the lead candidate in its gene-therapy pipeline, an experimental treatment for a rare inherited enzyme disorder known as Tanager syndrome, has cleared its first major clinical hurdle. The company completed dosing of a 12-patient initial cohort in its Phase 1 trial without a serious adverse event, meeting the study’s primary safety endpoint roughly a year after the company closed a $64 million funding round.
“This is the moment where the science either holds up outside a lab notebook or it doesn’t,” said Chief Executive Elena Marchetti. “It held up.” Marchetti said early biomarker readings, which the company is not yet disclosing in detail, were “encouraging enough” that Kestrel plans to move directly into an expanded Phase 1b cohort rather than pausing for a full data lock.
From a Kincaid lab bench to a clinical trial site
The therapy traces back to Dr. Wei-Lin Tan’s research lab at Kincaid University, where Kestrel spun out five years ago. Tan, who still consults for the company part time, said the milestone validates a bet the university and its early investors made when they chose to commercialize the underlying gene-editing technique in Bellwater rather than license it to an out-of-state drugmaker. That decision, and the funding round that followed, were detailed in an earlier Times report on Kestrel’s $64 million Series C.
I have watched a lot of good science die in a Phase 1 trial for reasons that had nothing to do with whether the science was right. Getting through this cohort clean doesn’t guarantee anything, but it means we get to keep going.
Dr. Wei-Lin Tan, Kincaid University
Tanager syndrome, which prevents the body from properly processing a liver enzyme and can cause organ damage over time, affects a small number of patients nationally, meaning Kestrel had to recruit across four trial sites outside Bellwater to fill the first cohort. Marchetti said enrollment took nearly two months longer than the company had projected, a delay she attributed to the rarity of the condition rather than any problem with the therapy itself.
Investors watch the next phase closely
Simone Hartley, a biotechnology analyst who tracks small-cap gene-therapy companies for an investment research firm, said clearing a first cohort without safety concerns is a real milestone but not a guarantee of anything further. “The graveyard of gene therapy is full of companies that looked exactly like this a year before they didn’t,” Nair said. “Phase 2 is where efficacy has to show up, and that’s a much harder bar.”
Marchetti said Kestrel expects to begin the expanded cohort within the quarter and to have enough data to decide on a Phase 2 design within the next year. She said the milestone also affects how the company deploys the remainder of its Series C funding, including a decision the company has not yet finalized about where to locate a planned second manufacturing facility.
“We built our hiring plans and our facility plans around the assumption that this drug would clear this exact hurdle,” Marchetti said. “Now we get to actually make those decisions instead of hedging them.”
The company’s Foundry Row headquarters, a converted warehouse space it shares with other tenants at Forge Bellwater, is already at capacity for laboratory bench space, a constraint that has become common among the neighborhood’s growing biotech tenants and is explored in a recent report on the lab space crunch facing Foundry Row’s biotech cluster.
Marchetti said the company has continued hiring laboratory scientists and manufacturing technicians through the trial’s early phase, though she declined to give an updated headcount ahead of a report the company plans to release later this year. Tan said she has noticed a shift in how graduate students at Kincaid talk about the company’s progress.
“A year ago people were asking whether Kestrel would still exist in five years,” Tan said. “Now they’re asking if there will be an opening in the manufacturing group. That’s a very different conversation to be having in a hallway on campus.”
Nair cautioned that the biomarker data Kestrel has shared publicly so far is limited, and that outside analysts won’t have a clear read on the drug’s actual efficacy until the company releases fuller results, which she said is typical for a company at this stage but still worth flagging for investors watching the stock of any of Kestrel’s publicly traded backers. “Enthusiasm ahead of data is normal in this industry,” she said. “It’s also how a lot of money gets misallocated.”
Marchetti said the company plans to share topline safety data from the full expanded cohort at a medical conference within the year, a presentation she said would mark the next real test of whether Bellwater’s bet on biotech continues to pay off.
The milestone also carries weight beyond Kestrel’s own balance sheet. Nakamura, the Bellwater Chamber of Commerce’s executive director, said the trial result has already come up in conversations with other employers she is trying to recruit to Foundry Row. “A clinical trial milestone doesn’t sound like an economic development story until you realize how many other decisions are waiting on it,” Nakamura said. “Landlords, other biotech founders, even the community college’s program planners are watching whether Kestrel keeps growing or stalls out.”
Marchetti said the company has no plans to slow its local hiring while it awaits fuller trial data, and that roughly a third of the positions it has filled over the past year went to graduates of Bellwater-area training programs rather than out-of-state transplants. “That number needs to keep climbing if this is going to look like the kind of growth this city actually asked for,” she said.